Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab tapering in rheumatoid arthritis
NCT06003283Phase 4Recruiting
- Sponsor
- UZ Leuven
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in rheumatoid arthritis (RA), sponsored by UZ Leuven. Started Jan 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06003283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003283.